The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...

Like many other major pharmaceutical companies, AstraZeneca is facing a series of patent cliffs for key treatments in its ...

In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent ...

The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public ...

Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.

See the latest Daiichi Sankyo Co Ltd stock price (4568:XTKS), related news, valuation, dividends and more to help you make your investing decisions.

Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market in the UK, through a ground-breaking collaboration with AstraZeneca.

Daiichi Sankyo is a commercial-stage biopharmaceutical company that is in strong financial health. As of fiscal 2024, it had a debt/EBITDA ratio of 0.3 times and over JPY 700 billion in cash and ...

Additionally, Daiichi Sankyo is banking on its ADC platform to target specific antigens and proteins as it explores more treatment options in its pipeline, including patritumab deruxtecan, ifinatamab ...

AstraZeneca and Daiichi Sankyo’s Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer. British pharmaceutical company AstraZeneca said Tuesday that ...